Company NextCell Pharma AB Nasdaq Stockholm
Equities
SE0009723125
Biotechnology & Medical Research
Business Summary
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cell Therapies
100.0
%
| 6 | 100.0 % | 10 | 100.0 % | +80.96% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Sweden
100.0
%
| 6 | 100.0 % | 10 | 100.0 % | +80.96% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Mathias Svahn
CEO | Chief Executive Officer | 48 | 14-03-18 |
Edvard Smith
FOU | Founder | 73 | 14-03-18 |
Patrik Fagerholm
DFI | Director of Finance/CFO | 57 | 21-08-31 |
Sofia Sisay
CTO | Chief Tech/Sci/R&D Officer | 43 | 21-12-31 |
Lindsay Davies
CTO | Chief Tech/Sci/R&D Officer | 45 | 19-12-31 |
Corporate Officer/Principal | 38 | 17-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 74 | 14-03-18 | |
Edvard Smith
FOU | Founder | 73 | 14-03-18 |
Camilla Sandberg
BRD | Director/Board Member | 57 | 16-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 72,196,998 | 58,524,881 ( 81.06 %) | 0 | 81.06 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+22.10% | 47.07B | |
+46.45% | 42.06B | |
-3.12% | 39.98B | |
+36.10% | 33.02B | |
-6.30% | 27.9B | |
+18.71% | 27.63B | |
+46.15% | 14.37B | |
+44.52% | 13.45B | |
+0.19% | 12.03B |